Godavari Biorefineries Secures European Patent for Breakthrough Anticancer Molecule

Godavari Biorefineries Ltd (GBL) has been granted a European patent for its novel anticancer molecule, marking a major milestone in its R&D-led diversification into life sciences. The patent, awarded under the European Patent Convention, recognizes GBL’s proprietary compound designed to target cancer stem cells, particularly in breast and prostate cancers.

 

The patented molecule is part of a broader pipeline developed by GBL’s Sathgen Biotech division, which focuses on oncology, regenerative medicine, and bio-based therapeutics. The innovation is built on a sugarcane-derived platform, aligning with the company’s ethos of green chemistry and sustainable biotech.

 

This development not only strengthens GBL’s intellectual property portfolio but also opens doors for licensing, clinical trials, and global partnerships in the oncology space. It reflects India’s growing footprint in bio-innovation and the convergence of agro-industrial expertise with pharmaceutical research.

 

Key Highlights:

Source: Rediff Money – Godavari Biorefineries Patent Announcement